ライフサイエンスコーパス: hair loss

1 alp including androgenetic alopecia (pattern hair loss).

2 um of the hair follicle and induce alopecia (hair loss).

3 er root sheath resulted in subsequent severe hair loss.

4 nt and cycling, eventually leading to severe hair loss.

5 nvolved either directly or indirectly in the hair loss.

6 petitive hair pulling that causes noticeable hair loss.

7 minoxidil is effective at retarding further hair loss.

8 ng the 1 mg/day preparation for male-pattern hair loss.

9 dulating inflammatory response in autoimmune hair loss.

10 developed fewer papillomas and had systemic hair loss.

11 SA in men aged 40-60 years with male-pattern hair loss.

12 engineer hair follicles for the treatment of hair loss.

13 appear malnourished, and exhibit progressive hair loss.

14 kine production in the development of patchy hair loss.

15 be useful to prevent chemotherapy-associated hair loss.

16 AA) is one of the most common forms of human hair loss.

17 probably very rare, between vaccinations and hair loss.

18 ctivate hair growth in animals with complete hair loss.

19 llent in vivo model for chemotherapy-induced hair loss.

20 ed wearing a wig or hat because of extensive hair loss.

21 a is an immune-mediated, nonscarring form of hair loss.

22 receptor signaling in mediating DXR-induced hair loss.

23 s for the management of chemotherapy-induced hair loss.

24 sis in hair matrix keratinocytes followed by hair loss.

25 TRA treatment, including skin irritation and hair loss.

26 d here suggest novel approaches to reversing hair loss.

27 minosis A from inadequate vitA intake causes hair loss.

28 In humans, excess RA is associated with hair loss.

29 hair differentiation and cycling, leading to hair loss.

30 ty, hyperkeratosis, scaling, skin folds, and hair loss.

31 ndant skin, papillomas, shortened nails, and hair loss.

32 volvement of the innate immune system in the hair loss.

33 and chest/abdomen (38.1% v 9.1%), as well as hair loss (14.0% v 6.3%).

34 neutrophil and eosinophil infiltrates but no hair loss (15 of 15).

35 significantly lower than in normals without hair loss (59.5 [40.8, 78.1]).

36 tosis in the hair follicle (HF) resulting in hair loss, a common side effect of cancer therapy.

37 ng of a new recessive mouse mutation causing hair loss, a new wavy-coated phenotype appeared.

38 hia is a rare, recessively inherited form of hair loss affecting both males and females and is charac

39 nificantly more likely to have less than 50% hair loss after the fourth chemotherapy cycle compared w

40 tions included 16 with positive rechallenge (hair loss after vaccination on more than 1 occasion), 4

41 Having noted increasing hair loss among our patients treated with voriconazole,

42 system is associated with a lower amount of hair loss among women receiving specific chemotherapy re

43 on in families who show an inherited form of hair loss and a hair growth defect.

44 with more wrinkling, whereas female pattern hair loss and a higher free androgen index were associat

45 proliferation of basal layer cells, leads to hair loss and impairs regeneration after wounding.

46 with mild dryness of the tail accompanied by hair loss and inflammation at the base of the tail.

47 hese findings suggest treatments for wounds, hair loss and other degenerative skin disorders.

48 ovide potential targets for the treatment of hair loss and other disorders of skin and hair.

49 opportunities for developing treatments for hair loss and other skin disorders.

50 itor 2-difluoromethylornithine could prevent hair loss and partially normalize skin histology if admi

51 erozygous mice are characterized by repeated hair loss and regrowth, and homozygous fetuses die at bi

52 pattern, with regionally cyclic episodes of hair loss and regrowth, and ultimately progresses to alo

53 Sfn(+/Er) mice are characterized by repeated hair loss and regrowth, whereas Sfn(Er/Er) mice die at b

54 ormalities, including cyclic and progressive hair loss and sebaceous gland hypertrophy.

55 onset excessive grooming with mild-to-severe hair loss and self-injury.

56 The Hr-/- phenotype includes both hair loss and severe wrinkling of the skin.

57 pulsive grooming behaviour leading to facial hair loss and skin lesions; both behaviours are alleviat

58 so revealed that IR induced HF dystrophy and hair loss and suppressed WNT signaling in a p53- and dos

59 Our model suggests that only when hair loss and sweating ability reach near-modern human l

60 EAA (average disease duration 14 years, 95% hair loss) and six control subjects.

61 striking delays in eyelid opening, wavy fur, hair loss, and epidermal hyperplasia with increased leve

62 cterized by delayed hair growth, progressive hair loss, and excessive accumulation of dermal choleste

63 ion causes sebaceous gland (SG) hypertrophy, hair loss, and extracutaneous abnormalities including gr

64 ficient phenotype, including stunted growth, hair loss, and iron-deficient erythropoiesis.

65 e identified with obstructed airways, cyclic hair loss, and severe immunodeficiency subsequent to the

66 The disease was characterized by erythema, hair loss, and the development of scales and crusts.

67 erse events of loss of taste, muscle cramps, hair loss, and weight loss.

68 N) mice differ from other Hr mutants in that hair loss appears as the postnatal coat begins to emerge

69 isms controlling human hair growth and scalp hair loss are poorly understood.

70 This dermatitis is accompanied by localized hair loss associated with formation of utriculi and derm

71 vs no scalp cooling was associated with less hair loss at 4 weeks after the last dose of chemotherapy

72 , poor hair anchoring ability, and premature hair loss at early telogen phase of the hair cycle, resu

73 ounds in a neonatal rat model of CIA reduced hair loss at the site of application in 33 to 50% of the

74 Runted mice showed hair loss at weaning.

75 Specifically, we postulate progressive hair loss being selected and this allowing individuals t

76 n elevated levels of RA in skin and cyclical hair loss; both are prevented by dietary retinol depriva

77 fter birth and gradually led to nearly total hair loss by 8 mo.

78 Hair loss can be a psychologically devastating adverse e

79 simplex is a rare autosomal dominant form of hair loss characterized by hair follicle miniaturization

80 atrichia is a rare form of hereditary human hair loss, characterized by the complete shedding of hai

81 We found in the SAM P(8) strain that hair loss, coarseness of hair texture, and ulceration of

82 1) greater decrease in the surface area with hair loss, compared with the hydrocortisone group at all

83 is a common heritable and androgen-dependent hair loss condition in men.

84 Hair loss developed by 3 mo after birth and gradually le

85 vels, and hemoglobin levels of women without hair loss differed from the means in each alopecia group

86 used for the treatment of a T cell-mediated hair loss disease (alopezia areata).

87 a areata (AA) is a non-scarring inflammatory hair loss disease with a complex autoimmune etiopathogen

88 Alopecia areata is an inflammatory hair loss disease with a major genetic component.

89 Alopecia areata is a suspected autoimmune hair loss disease.

90 normal hair growth, the basis of hereditary hair loss diseases, and the origin of follicle-based tum

91 -resistant rickets have a similar congenital hair loss disorder caused by mutations in hairless (HR)

92 cia areata (AA), a non-scarring inflammatory hair loss disorder, is a complex disease determined by g

93 This group of permanent hair loss disorders can be classified into distinct subg

94 lian hairless (Hr) gene result in congenital hair loss disorders in both mice and humans, the precise

95 additional undesirable phenotypes, including hair loss, dry eye, leukocytosis, xanthomatosis, and a r

96 he K14-DN-Clim mice also develop progressive hair loss due to dysfunctional hair follicles that fail

97 autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the

98 a that was clearly attributable to the drug, hair loss, extravasation necrosis, or decreases in eject

99 e assigned cream twice daily to the areas of hair loss for 2 cycles of 6 weeks on, 6 weeks off, for a

100 fective and safe for treating female pattern hair loss (FPHL)?

101 Genotoxicity-induced hair loss from chemotherapy and radiotherapy is often en

102 epair can be a potential approach to prevent hair loss from chemotherapy and radiotherapy.

103 ormal group consisted of 11 subjects without hair loss from the same referral base and source populat

104 acterized by androgen-dependent, progressive hair loss from the scalp.

105 were off voriconazole for at least 3 months, hair loss had stopped in 94 (82%) and regrowth had begun

106 Although hair loss has been reported in association with heredita

107 ysis of preoperative risk factors found body hair loss (hazard ratio, 17.3; P > 0.005), preoperative

108 nocyte responses during chemotherapy-induced hair loss, however, remain largely unknown.

109 w growth retardation, cyclic and progressive hair loss, hyperplastic epidermis, abnormal hair follicl

110 The histologic changes associated with the hair loss, i.e., peri-, and intrafollicular inflammatory

111 3tm1stan mice develop phenotypic runting and hair loss, identical to that of the mouse mutant, Dsg3ba

112 inflammatory reaction resulting in complete hair loss in 67% of the grafts by 10 weeks.

113 17 gene (mK17) causes severe but reversible hair loss in a strain-dependent fashion in mouse.

114 ASCs can accelerate wound-healing and reduce hair loss in acid-burn skin injury.

115 Alopecia areata (AA)-like hair loss in C3H/HeJ mice provides an excellent model fo

116 t coat-hair whitening, which preceded patchy hair loss in depigmented areas.

117 In this study we examine the mechanism of hair loss in GsdmA3(Dfl)/+ mice.

118 grafts from AA-affected C3H/HeJ mice induced hair loss in histocompatible C3H/OuJ mice (four of 13) a

119 ause papular atrichia in humans and complete hair loss in mice and other mammals.

120 Alopecia areata (AA) is characterized by hair loss in patches and may progress to total loss of s

121 DFMO treatment-associated hair loss in PKC epsilon transgenic mice was accompanied

122 However, DFMO treatment led to marked hair loss in PKC epsilon transgenic mice.

123 c beta cells; wound healing and irreversible hair loss in the skin; and permanent moderate deafness d

124 Hair loss in these mice is similar to that seen in prima

125 lecular phenotypes to identify the basis for hair loss in this model.

126 niaturization of hair follicles and eventual hair loss in wild-type mice and in humans.

127 ame doses of gamma-radiation caused dramatic hair loss in wild-type mice when administered in the mor

128 ated scarring, disfigurement, and persistent hair loss, in addition to their long-term impact on psyc

129 Then, as our ancestors' hair loss increased and sweating ability improved over e

130 ace, education, and marital status, survivor hair loss increased risk of anxiety (RR, 1.60; 95% CI, 1

131 py for inhibiting keratinocyte apoptosis and hair loss induced by chemotherapy.

132 f GVHD, as measured by profound weight loss, hair loss, inflammation of foot pads and ears, and profo

133 Hair loss is a distressing side-effect of cancer therapy

134 Our analysis suggests that patterned hair loss is associated with a higher risk of fatal pros

135 l numbers fluctuate over the hair cycle, and hair loss is associated with gradual depletion/atrophy o

136 human in vivo model for chemotherapy-induced hair loss is closer to clinical reality than to any earl

137 ommon, but may be distressing, especially if hair loss is extensive.

138 itotic peak, compared with the evening, when hair loss is minimal.

139 Chemotherapy-induced hair loss is one of the most devastating side effects of

140 There are several forms of hereditary human hair loss, known collectively as alopecias, the molecula

141 Because hair loss may be a surrogate measure of androgenic activ

142 Significantly more episodes of drowsiness, hair loss, nausea, and dry or itchy scalp were reported

143 d-type mice, p53-deficient mice show neither hair loss nor apoptosis in the HF keratinocytes that mai

144 ale (grade 0 [no hair loss] or grade 1 [<50% hair loss not requiring a wig] were considered to have h

145 Severe hair loss observed in PKC epsilon transgenic mice on DFM

146 rly androgenetic alopecia (AGA) is patterned hair loss occurring before age 30 years.

147 Hair loss of 50% or less (Dean score of 0-2) was seen in

148 iation and cycling, leading to a progressive hair loss of mutant (MT) mice.

149 disease of the hair follicle that results in hair loss of varying severity.

150 The impact of disfigurement and hair loss on HRQOL (ie, Medical Outcomes Short Form-36)

151 f severity that ranges from patchy localized hair loss on the scalp to the complete absence of hair e

152 Hair loss on the scalp was noted in 120 (96%), arms and

153 size without causing leukocytosis, dry eye, hair loss, or a reduced life span.

154 Hair loss, or alopecia, may occur as a primary skin diso

155 dverse Events version 4.0 scale (grade 0 [no hair loss] or grade 1 [<50% hair loss not requiring a wi

156 me was the change in scalp surface area with hair loss over 24 weeks following enrollment.

157 ommon form of alopecia areata (AA) involving hair loss over the entire scalp and body and is often di

158 understanding the genetic etiology of human hair loss over the previous decade, there remain a numbe

159 at the start of follow-up and recalled their hair-loss patterns at age 45 years.

160 The runting and hair loss phenotype of DSG3 -/- mice is identical to tha

161 Defolliculated (Gsdma3(Dfl)/+) mice have a hair loss phenotype that involves an aberrant hair cycle

162 Surprisingly, K5.CtBP1 pups also exhibited a hair loss phenotype.

163 in, and increased Zipro1 dosage results in a hair-loss phenotype associated with increased epithelial

164 d (Dfl) is a spontaneous mouse mutant with a hair-loss phenotype that includes altered sebaceous glan

165 pathological skin conditions (stress-induced hair loss, psoriasis, atopic dermatitis).

166 in size, with eyelid irritation and sporadic hair loss resembling the cyclical alopecia observed in m

167 rement (RR, 1.19; 95% CI, 1.05 to 1.35), and hair loss (RR, 1.26; 95% CI, 1.09 to 1.47).

168 e risk [RR], 2.42; 95% CI, 2.22 to 2.65) and hair loss (RR, 4.24; 95% CI, 3.63 to 4.95).

169 the key features of the chemotherapy-induced hair loss seen in patients with cancer and (ii) this hum

170 lso have marked glutathione (GSH) depletion, hair loss, skin erosion, gut mucosal atrophy, and deplet

171 mice showed unkempt and greasy hair coat and hair loss soon after birth.

172 Msx2-deficient mice exhibit progressive hair loss, starting at P14 and followed by successive cy

173 ssor provides a molecular basis for specific hair loss syndromes in both humans and mice.

174 e alopecia mutation (jal) display patches of hair loss that appear as soon as hair develops in the ne

175 After adjusting for baseline hair loss, the clobetasol group had a statistically sign

176 optosis in the hair follicles (HF) and cause hair loss, the most common side effect of chemotherapy.

177 Self-estimated hair loss using the Dean scale was assessed 4 weeks afte

178 il onset and the extent and reversibility of hair loss, varied widely.

179 Conversely, patterned hair loss was not statistically significantly associated

180 owever, the thermoregulatory explanation for hair loss was supported.

181 A Dean scale score of 0 to 2 (</=50% hair loss) was defined as treatment success.

182 In a mouse model for chemotherapy-induced hair loss, we demonstrate that p53 is essential for this

183 ecia, additional questions about reversal of hair loss were asked after voriconazole had been stopped

184 ported scarring/disfigurement and persistent hair loss were examined in 14,358 survivors and 4,023 si

185 ny oral medication or hormonal treatment for hair loss were excluded from the study.

186 diac hypertrophy, leukopenia, and weight and hair loss were not detected with CuDox-LTSLs after the 2

187 irty-two age-matched men with no evidence of hair loss were recruited as controls.

188 ged 19 to 30 years presenting with patterned hair loss were recruited as study participants.

189 , 355 men aged 40-60 years with male-pattern hair loss were stratified by age decade (40-49 years and

190 ownregulated Shh gene expression and induced hair loss, whereas doxorubicin or Ara-C did not.

191 m 6 weeks of age, mice underwent progressive hair loss which correlated with the development of derma

192 reased risk for disfigurement and persistent hair loss, which is associated with future emotional dis

193 Adult Dgat(-/-) mice had dry fur and hair loss, which were associated with atrophic sebaceous

194 Alopecia areata is an idiopathic cause of hair loss with limited therapeutic repertoire.

195 ed the association of dermatologist-assessed hair loss with prostate cancer-specific mortality in the

196 the list of genes with effects on behavioral hair loss, with the added twist that this time the gene

197 ausea, vomiting, constipation, diarrhea, and hair loss) within three randomized trials.

198 on between scalp cooling and reduced risk of hair loss would be demonstrated if 50% or more of patien

199 or tissue engineering and new treatments for hair loss, wound healing and other degenerative skin dis

200 "dystrophic catagen" initially enhanced the hair loss, yet subsequently promoted accelerated hair fo